Galapagos NV header image

Galapagos NV

GLPG

Equity

ISIN BE0003818359 / Valor 2130343

Euronext - Euronext Amsterdam (2025-10-20)
EUR 29.62+1.58%

Galapagos NV
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Galapagos NV is a company focused on accelerating transformational innovation through groundbreaking science, an entrepreneurial spirit, and a collaborative mindset. In 2022, the company expanded into the field of oncology, CAR-T, and antibody therapy research and development through the acquisitions of CellPoint and AboundBio. These acquisitions have equipped Galapagos NV with end-to-end CAR-T development capabilities, including a decentralized point-of-care manufacturing model and state-of-the-art fully human antibody-based capabilities for the development of next-generation CAR-Ts and biologics.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (13.10.2025):

Galapagos NV has released its financial results for the first half of 2025. The company reported a total net revenue of €140.265 thousand, reflecting a slight decrease compared to the same period in the previous year. Despite increased research and development expenses, Galapagos NV continues to invest heavily in its pipeline, aiming for long-term growth and innovation.

Revenue Overview

Total net revenues for the six months ended June 30, 2025, amounted to €140.265 thousand, a minor decline from €140.305 thousand in the same period of 2024. Supply revenues decreased to €18.486 thousand from €19.105 thousand, while collaboration revenues remained stable at €121.779 thousand.

Operating Loss

The operating loss widened significantly to €215.735 thousand in the first half of 2025, compared to €71.312 thousand in the previous year. This increase is primarily attributed to a rise in R&D expenses, which surged to €278.027 thousand from €145.225 thousand.

Net Profit/Loss

Galapagos NV reported a net loss of €259.151 thousand for the first six months of 2025, reversing a net profit of €99.205 thousand from the same period in 2024. The loss was influenced by negative net financial results of €45.056 thousand.

Cash and Cash Equivalents

The company maintains a healthy cash position with €71.669 thousand in cash and cash equivalents as of June 30, 2025, slightly down from €72.328 thousand in the previous year. Financial investments remain robust at €3.019.835 thousand.

Employee Count

As of the end of June 2025, Galapagos NV employed 558 individuals, reflecting a reduction from 683 employees in the first half of 2024. This adjustment is part of the company's ongoing efforts to optimize operational efficiency.

Summarized from source with an LLMView Source

Key figures

6.16%1Y
-33.5%3Y
-73.5%5Y

Performance

33.4%1Y
29.6%3Y
36.1%5Y

Volatility

Market cap

2267 M

Market cap (USD)

Daily traded volume (Shares)

47,577

Daily traded volume (Shares)

1 day high/low

26.36 / 25.88

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

GSK PLC
GSK PLC GSK PLC Valor: 120042705
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.48%USD 44.12
Sanofi SA
Sanofi SA Sanofi SA Valor: 699381
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.17%EUR 86.58
Eurofins Scientific SE
Eurofins Scientific SE Eurofins Scientific SE Valor: 58317129
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.21%EUR 63.90
AstraZeneca PLC
AstraZeneca PLC AstraZeneca PLC Valor: 163523
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.97%USD 83.87
Siemens Healthineers AG
Siemens Healthineers AG Siemens Healthineers AG Valor: 40652181
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.23%EUR 48.37
Asker Healthcare Group AB
Asker Healthcare Group AB Asker Healthcare Group AB Valor: 143378021
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.83%SEK 84.94
Dynavox Group AB
Dynavox Group AB Dynavox Group AB Valor: 114900704
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.39%SEK 102.70
International Flavors & Fragrances Inc
International Flavors & Fragrances Inc International Flavors & Fragrances Inc Valor: 941876
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.40%USD 64.64
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc Apellis Pharmaceuticals Inc Valor: 30132056
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
10.40%USD 27.07
Alcon Inc.
Alcon Inc. Alcon Inc. Valor: 43249246
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.67%CHF 59.92